YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients. Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico. The agreement…
Knight Therapeutics MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement with Kyowa K…
Kyowa Kirin (TSE:4151) has come into focus after a broad rethink of pharmaceutical valuations in Tokyo. This has drawn attention to how its share performance lines up with its current earnings profile and research pipeline. Over the past f…
Asian stock markets turned in a mixed and generally muted Wednesday, as traders watched Persian Gulf PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Company Logo Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drug…
Strengthens Kyowa Kirin's commitment to expanding access to medicines Reinforces investment in U.S. manufacturing and innovation TOKYO and PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a…
(Bloomberg) -- The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd. Most Read from Bloomberg Nvidia to…
Cognizant Technology Solutions recently announced it will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan, integrating experiment planning, execution, data capture, an…
Cognizant Technology Solutions stock has climbed sharply in the past month, yet multiple valuation checks still suggest the shares may be pricing in less than the company's underlying worth. Both an intrinsic value estimate using a Discoun…
Kyowa Kirin Co., Ltd. recently reported half-year 2026 results, with sales rising to ¥263,629 million and net income reaching ¥30,618 million, alongside basic earnings per share from continuing operations of ¥58.48. This performance highli…
* Kyowa Kirin press release [https://ir.kyowakirin.com/en/library/earnings/earnings0/main/0118/teaserItems1/00/linkList/0/link/summary_2026_q2_en.pdf] (KYKOF [https://seekingalpha.com/symbol/KYKOF]): 1H Non-GAAP EPS of ¥103.26. * Revenue o…
Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy. Approval applies across…
Companies like Biogen and Royalty Pharma (Litifilimab), Biogen and UCB(Dapirolizumab pegol), Idorsia Pharmaceuticals and Viatris (Cenerimod), Novartis (Ianalumab, YTB3231), Kyowa Kirin (KK-4277), and others are advancing late, mid, and ear…
Strategic collaboration at Sanford, North Carolina facility, currently under construction, to optimize cGMP validation, accelerate time-to-market for complex biologics, and shore up U.S. medicine supply TOKYO and PRINCETON, N.J., June 30,…
Kyowa Kirin Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers Across both studies, mogamulizumab was associated with improved survival outcomes co…
[machine that makes capsules in a pharmaceutical laboratory - 3D rendering] Thibault Renard/iStock via Getty Images * Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) and Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/symbo…
Kyowa Kirin Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in Montreal, Canada PRINCETON,…
Kyowa Kirin New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages XLH Community GuidebookReaders can explore the content by topic or a…
Kura Oncology, Inc. – 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – – High rates of MRD n…
Kyowa Kirin New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin,…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Kyowa Kirin (TSE:4151) has been in focus after recent share price moves, with the stock around ¥2,326 and mixed returns over…
Kura Oncology, Inc. – 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax…
Company Logo Market opportunities for Romiplate are driven by the increasing diagnosis of immune thrombocytopenia (ITP), expansion into additional thrombocytopenia conditions, strong commercial sales, global expansion, and growing physicia…
Kyowa Kirin Expanded dosing options support individualized treatment for adults with XLH PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., today announced the U.S. Food…
This article first appeared on GuruFocus. Net Product Revenue: $5.8 million from KOMZIFTI sales in Q1 2026. Collaboration Revenue: $12.5 million from Kyowa Kirin partnership in Q1 2026. Research and Development Expenses: $65.3 million in Q…
Kura Oncology, Inc. – Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses…
Kyowa Kirin Public drug coverage now provides eligible adults access to CRYSVITA, the only approved treatment for X-linked hypophosphatemia (XLH), a lifelong progressive disease TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Canada,…
Orchard Therapeutics (Europe) Limited Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom LONDON, April 30, 2026 (GLOB…
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announ…
We recently compiled a list of the 11 Best Kid-Friendly Stocks to Invest In. Amgen Inc. (NASDAQ:AMGN) is one of the best kid-friendly stocks on our list. On March 3, TheFly reported that Kyowa Kirin Co., Ltd. disclosed that it is discontin…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Amgen (NasdaqGS:AMGN) and Kyowa Kirin have stopped all clinical trials of rocatinlimab after newly identified safety concern…
This article first appeared on GuruFocus. Net Product Revenue: $2.1 million from KOMZIFTI sales in Q4 2025. Collaboration Revenue: $15.2 million from Kyowa Kirin partnership in Q4 2025, compared to $53.9 million in Q4 2024. Research and De…
Asian stock markets retreated Wednesday, as traders weighed the Middle East war, rising oil prices, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
TOKYO AND PRINCETON, Japan and the U.S., March 03, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the discontinuation of all ongoing clinical t…
Grünenthal acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. Through this acquisition, Grünenthal assumes the s…